Core Insights - Premier Graphene Inc. and HGI Industrial Technologies are positioned for success in the cannabis and industrial hemp sectors, highlighted by their participation in an international forum in Mexico City [3][4] - The companies have secured a significant COFEPRIS license, allowing them to import and commercialize cannabinoid products in Mexico, marking a major regulatory achievement [4][6] - Innovations in industrial hemp composites and graphene-enhanced medical applications are being developed, positioning the companies at the forefront of biotechnology and materials science [7][12] Regulatory and Market Opportunities - The relationship with Santa Rosa Green Seeds and the COFEPRIS license provides Premier Graphene with a competitive edge in the cannabinoid market [4][6] - The forum discussed the landscape of federal cannabis legalization in Mexico, with HGI recognized for obtaining the Amparo, enabling compliant operations [8] - The recent executive order by President Donald Trump reclassifying cannabis may enhance research and development opportunities in the medical cannabis sector [9][10] Technological Innovations - Advances in using CBD-doped graphene for targeted drug delivery systems are being explored, which could revolutionize treatment for diseases like cancer [7][12] - The integration of cannabinoids and graphene is seen as a new frontier in bioelectric medicine, focusing on restoring healthy electrical signaling in the body [12] Company Profiles - Premier Graphene Inc. focuses on developing high-performance graphene materials from sustainable sources, aiming to lead in innovation and sustainability across multiple industries [13] - HGI Industrial Technologies specializes in industrial hemp development and cannabinoid imports, positioning itself as a leader in the biotech and defense sectors in Mexico [14]

Core Insights - The event highlighted the collaboration between Premier Graphene Inc. and HGI Industrial Technologies, focusing on the future of cannabis, industrial hemp, and advanced materials science in Mexico [1][2] - Premier Graphene has secured a significant regulatory milestone with an official importing license from COFEPRIS, allowing for the importation and commercialization of cannabinoid products [2][4] - The forum discussed advancements in industrial hemp composites and medical applications, positioning Premier and HGI at the forefront of biotechnology and materials science [3][8] Regulatory Developments - Premier's relationship with Santa Rosa Green Seeds enhances its market position, particularly with the exclusive importing license from COFEPRIS [2][11] - HGI Industrial Technologies has obtained the Amparo, enabling it to legally initiate operations in compliance with Mexican regulations [4][10] - The recent executive order by President Donald Trump reclassifying cannabis may significantly impact the cannabis industry, promoting research and development [5][6] Technological Innovations - Dr. Stuart Titus emphasized the potential of cannabinoids in bioelectric medicine, particularly in cancer treatment through targeted drug delivery systems using CBD-doped graphene [3][7] - The integration of cannabinoids and graphene is seen as a new frontier in bioelectric medicine, enhancing cellular communication and restoring healthy electrical signaling [7][8] Market Positioning - Premier Graphene is committed to addressing the needs of the defense and technology sectors while aiming to fill the global gap in graphene production [8][9] - HGI Industrial Technologies is positioned to become a leading importer and developer of legal cannabinoid products in Mexico, leveraging its expertise in cultivation and regulatory compliance [10][11]

watch nowPresident Donald Trump's move Thursday to sign an executive order easing federal restrictions on marijuana — and clearing the way for a Medicare pilot program covering CBD — caps a coordinated, yearlong push by the cannabis industry that combined traditional lobbying, sizable political donations, data-driven messaging and direct outreach to the president's inner circle, industry insiders told CNBC.Despite long-standing GOP opposition to loosening drug laws — including a small wave of bills from law ...

Trump just made the biggest federal cannabis move in over 50 years, and Wall Street is already reacting. I'm Bernie Gomez at CNBC headquarters, and President Trump has officially signed an executive order reclassifying cannabis, moving it out of schedule one, the same category as heroin, and into schedule 3. That change eases restrictions on research, banking, and taxes, and could reshape the entire cannabis industry.Now, Trump says the move is about patients, including veterans, seniors, and people with ch ...

Core Viewpoint - The reclassification of marijuana by President Trump as a Schedule III drug opens up significant opportunities for the cannabis industry, particularly for companies like Scott's Miracle Grow and its Hawthorne subsidiary, which provides cannabis growing supplies [1][4][6]. Company Developments - Scott's Miracle Grow plans to combine its Hawthorne subsidiary with a dedicated pure-play cannabis company next year, indicating a strategic shift to capitalize on the evolving cannabis market [2][12]. - The CEO of Scott's Miracle Grow, Jim Hagadorn, expressed enthusiasm about the executive order, highlighting the culmination of a decade-long effort to achieve this change [3][4]. Industry Implications - The reclassification allows for increased medical research on cannabis, which was previously restricted under Schedule I classification, thus potentially leading to new medical applications and benefits [4][6]. - Legal cannabis businesses can now benefit from a reduced federal tax rate of 21%, down from an 80% rate, which was previously punitive and hindered profitability [6][7]. - The change is expected to help legitimate markets thrive while reducing the influence of illicit operators and protecting children [7][8]. Market Reactions - Following the announcement, there was initial stock price volatility, with some stocks experiencing a spike before settling down, indicating a "sell on the news" reaction from investors [11].

Core Viewpoint - The executive order signed by President Trump represents a significant shift in U.S. cannabis policy, reclassifying marijuana from Schedule I to Schedule III, which could have major implications for the cannabis industry and its financial landscape [1][2]. Industry Impact - The reclassification is seen as a financial lifeline for the cannabis industry, allowing companies to deduct standard expenses like rent and payroll for the first time due to exemption from IRS Code Section 280E [6]. - The move is expected to facilitate banking access and attract institutional capital that has previously been deterred by compliance concerns [6]. - Analysts anticipate that the changes, along with the Medicare pilot program, may draw major pharmaceutical companies into the cannabis sector to pursue federally insured revenue [6]. Market Reaction - Following the announcement, shares of cannabis companies showed mixed results: Tilray Brands increased by approximately 6%, while Trulieve and Green Thumb Industries saw declines of about 15% and 5%, respectively. The AdvisorShares Pure US Cannabis ETF fell by more than 10% [5]. Regulatory Developments - The Centers for Medicare and Medicaid Services is set to launch a pilot program allowing certain Medicare-covered seniors to receive free, doctor-recommended CBD products, which must comply with local and state laws [4]. - The executive order does not legalize marijuana for recreational use, but it may encourage further research into the effects of CBD [8]. Consumer Trends - CBD has gained popularity in various consumer goods, but the FDA has not fully endorsed the compound, citing inconsistent benefits and potential risks associated with prolonged use [7].

（记者 胡玲） 每经AI快讯，莱茵生物（002166.SZ）12月17日在投资者互动平台表示，公司美国印州工厂于今年已升 级改造为综合提取工厂，但仍具备CBD的提取能力。 ...

In this articleTLRYWEED-CATarek Adieh, of Tampa, Florida, looks at cannabis flower from wholesaler Dep Kings at CHAMPS Trade Show at the Palmer Events Center Thursday, Sept. 11, 2025. Jay Jannar | Hearst Newspapers | Getty ImagesPresident Donald Trump is expected to sign an executive order this week that would broadly expand access to cannabis. Industry advocates, executives and researchers who spoke to CNBC said the changes would come with big implications for both consumers and the health care industry. T ...

Core Insights - Cannabis stocks may experience a rally due to potential new federal regulations for hemp-derived products and a more permissive stance from President Trump on marijuana [1][4][19] Company Performance - Verano Holdings reported revenues of $203 million, a slight increase from the previous quarter but a 6% decrease year-over-year, with a net loss of $44 million attributed to impairment charges and legal contingencies [2] - Tilray Brands' stock surged 22% in October following better-than-expected fiscal first-quarter results, indicating potential for recovery in the sector [3] Market Trends - The cannabis market is projected to reach a $160 billion global market by 2032, with a 40% growth in U.S. cannabis production value last year [6] - Daily or near-daily marijuana use in the U.S. has surpassed daily drinking, reflecting increasing popularity [5] Regulatory Developments - Trump's support for Medicare coverage of CBD and potential reclassification of marijuana could attract more companies to the U.S. cannabis market [4][19] - Congress is considering updates to the 2018 Farm Bill to establish federal standards for hemp-derived products, which could enhance market legitimacy and consumer safety [13][15] Investor Sentiment - Investor optimism has surged following Trump's video promoting CBD, with significant stock price increases for companies like Tilray and Aurora Cannabis [9][11] - The cannabis industry is hopeful that federal regulations could legitimize the market and attract institutional investors [17][18] Challenges and Concerns - Despite optimism, some Republican lawmakers are pushing for stricter regulations on hemp-derived products due to safety concerns, which could impact market dynamics [24][28] - The cannabis market remains largely unregulated, leading to potential safety issues and consumer exposure to mislabeled products [15][27]

Regulatory Landscape - The 2018 Farm Bill legalized hemp-derived CBD [3] - Potential reclassification of cannabis to schedule three could reduce criminal penalties and lower costs for companies [3] Market Implications - Reclassification could lead to more affordable CBD products for consumers [3] - Increased research into medical uses of cannabis may occur [3] Potential Benefits - Hemp-derived CBD may improve the quality of life for older adults [2] - CBD could be an alternative to expensive prescription drugs [2]